-
11.发明授权公开(公告)号：US09388199B2
公开(公告)日：2016-07-12
申请号：US14409882
申请日：2013-06-27
Applicant: NOVARTIS AG
Inventor： Eva Altmann , Ulrich Hommel , Edwige Liliane Jeanne Lorthiois , Jeurgen Klaus Maibaum , Nils Ostermann , Stefan Andreas Randl , Olivier Rogel , Anna Vulpetti
IPC: C07D403/06 , C07D403/14 , C07D471/04 , C07D403/12 , C07F7/08
CPC classification number: C07F7/0812 , C07D403/06 , C07D403/12 , C07D403/14 , C07D471/04
Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Abstract translation: 本发明提供式（I）化合物，其是制备本发明化合物的方法及其治疗用途，用作治疗眼部疾病的补体途径调节剂。 本发明还提供药理活性剂和药物组合物的组合。
-
12.发明申请公开(公告)号：US20150191462A1
公开(公告)日：2015-07-09
申请号：US14409903
申请日：2013-06-27
Applicant: NOVARTIS AG
Inventor： Ulrich Hommel , Edwige Liliane Jeanne Lorthiois , Jeurgen Klaus Maibaum , Nils Ostermann , Stefan Andreas Randl , Olivier Rogel , Anna Vulpetti
IPC: C07D471/04 , C07D401/14 , C07D403/14 , C07D417/14
CPC classification number: C07D471/04 , C07D401/14 , C07D403/14 , C07D417/14
Abstract: The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement alternative inhibitors for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Abstract translation: 本发明提供式I化合物：（I）制备本发明化合物的方法及其作为治疗眼部疾病的补体替代抑制剂的治疗用途。 本发明还提供药理活性剂和药物组合物的组合。
-
公开(公告)号：US11180460B2
公开(公告)日：2021-11-23
申请号：US16571405
申请日：2019-09-16
Applicant: Novartis AG
Inventor： Daniela Angst , Francois Gessier , Anna Vulpetti
IPC: C07D405/12 , C07D403/12 , A61K31/505 , A61K31/506 , A61P19/02 , C07D239/47 , C07D401/14 , C07D401/10 , C07D401/12 , A61P29/00 , A61P35/02
Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
-
![3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives](/abs-image/US/2021/08/19/US20210251996A1/abs.jpg.150x150.jpg)
14.发明申请公开(公告)号：US20210251996A1
公开(公告)日：2021-08-19
申请号：US16981208
申请日：2019-03-25
Applicant: NOVARTIS AG
Inventor： Luca Arista , Christina Hebach , Gregory John Hollingworth , Philipp Holzer , Patricia Imbach-Weese , Rainer Machauer , Niko Schmiedeberg , Anna Vulpetti , Thomas Zoller
IPC: A61K31/519 , C07D519/00 , C07D487/04 , A61P35/00
Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
-
公开(公告)号：US20180140602A1
公开(公告)日：2018-05-24
申请号：US15564463
申请日：2016-04-07
Applicant: Daniela Angst , John Byrd , Jason Dubovsky , Joseph A. Fraietta , Francois Gessier , Saar Gill , Amy Johnson , Carl H. June , Marcela Maus , Natarajan Muthusamy , David L. Porter , Marco Ruella , Anna Vulpetti , Mariusz Wasik , Novartis AG , The Trustees of the University of Pennsylvania
Inventor： Daniela Angst , John Byrd , Jason Dubovsky , Joseph A. Fraietta , Francois Gessier , Saar Gill , Amy Johnson , Carl H. June , Marcela Maus , Natarajan Muthusamy , David L. Porter , Marco Ruella , Anna Vulpetti , Mariusz Wasik
IPC: A61K31/505 , A61K35/17 , C07K16/28 , A61K31/506 , C07K16/30 , A61P35/00 , A61P35/02
CPC classification number: A61K31/505 , A61K31/506 , A61K35/17 , A61K45/06 , A61K2035/124 , A61K2039/505 , A61K2039/545 , A61P35/00 , A61P35/02 , C07K16/2803 , C07K16/30 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N5/0636 , A61K2300/00
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.
-
Patent Agency Ranking
16.发明申请公开(公告)号：US20150190457A1
公开(公告)日：2015-07-09
申请号：US14409893
申请日：2013-06-27
Applicant: NOVARTIS AG
Inventor： Eva Altmann , Ulrich Hommel , Edwige Liliane Jeanne Lorthiois , Jeurgen Klaus Maibaum , Nils Ostermann , Jean Quancard , Stefan Andreas Randl , Olivier Rogel , Anna Vulpetti
IPC: A61K38/05 , C07D403/12 , C07K5/062
CPC classification number: A61K38/05 , C07D403/06 , C07D403/12 , C07D403/14 , C07D417/14 , C07D471/04 , C07K5/06026
Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Abstract translation: 本发明提供式（I）化合物，其制备本发明化合物的方法及其作为治疗眼部疾病的补体途径调节剂的治疗用途。 本发明还提供药理活性剂和药物组合物的组合。
-
公开(公告)号：US11673868B2
公开(公告)日：2023-06-13
申请号：US17508054
申请日：2021-10-22
Applicant: Novartis AG
Inventor： Daniela Angst , François Gessier , Anna Vulpetti
IPC: C07D405/12 , C07D403/12 , A61K31/505 , A61K31/506 , C07D239/47 , C07D401/14 , C07D401/10 , C07D401/12 , A61P29/00 , A61P35/02
CPC classification number: C07D239/47 , A61K31/505 , A61K31/506 , A61P29/00 , A61P35/02 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12
Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
-
![Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors](/abs-image/US/2023/03/28/US11613543B2/abs.jpg.150x150.jpg)
公开(公告)号：US11613543B2
公开(公告)日：2023-03-28
申请号：US16981059
申请日：2019-03-22
Applicant: NOVARTIS AG
Inventor： Luca Arista , Christina Hebach , Gregory John Hollingworth , Philipp Holzer , Patricia Imbach-Weese , Julien Lorber , Rainer Machauer , Niko Schmiedeberg , Anna Vulpetti , Thomas Zoller
IPC: A61K31/519 , C07D487/04 , C07D519/00 , A61K45/06
Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
-
![N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives](/abs-image/US/2021/01/07/US20210002285A1/abs.jpg.150x150.jpg)
公开(公告)号：US20210002285A1
公开(公告)日：2021-01-07
申请号：US16981059
申请日：2019-03-22
Applicant: NOVARTIS AG
Inventor： Luca Arista , Christina Hebach , Gregory John Hollingworth , Philipp Holzer , Patricia Imbach-Weese , Julien Lorber , Rainer Machauer , Niko Schmiedeberg , Anna Vulpetti , Thomas Zoller
IPC: C07D487/04 , C07D519/00
Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
-
公开(公告)号：US10457647B2
公开(公告)日：2019-10-29
申请号：US15974190
申请日：2018-05-08
Applicant: Novartis AG
Inventor： Daniela Angst , Francois Gessier , Anna Vulpetti
IPC: C07D405/12 , C07D403/12 , A61K31/505 , A61K31/506 , C07D239/47 , C07D401/14 , C07D401/10 , C07D401/12 , A61P29/00 , A61P35/02
Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.03 seconds)
